Wada, Shuhei
Iwamoto, Kunihiro
Okumura, Hiroki
Hida, Hirotake
Hiraoka, Shuichi
Kamei, Aya
Mori, Daisuke
Yamada, Kiyofumi
Ando, Masahiko
Ozaki, Norio
Ikeda, Masashi
Funding for this research was provided by:
Meiji Seika Pharma
Article History
Received: 3 October 2023
Accepted: 23 January 2024
First Online: 30 January 2024
Declarations
:
: This study was approved by the Nagoya University Clinical Research Review Board (CRB4180004), and written informed consent was obtained from all enrolled patients before the study began. This study was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: SW has received speakers’ honoraria from Sumitomo Pharma. KI has received speakers’ honoraria from Eisai, Kyowa, Meiji Seika Pharma, MSD, Otsuka, Sumitomo Pharma, Taisho, Takeda, Towa, Viatris, and Yoshitomi, outside the submitted work. HO has no conflicts of interest to declare. HH has no conflicts of interest to declare. SH and AK are full-time employees of Meiji Seika Pharma. DM has no conflicts of interest to declare. KY has no conflicts of interest to declare. MA has received research grant from Kyowa Kirin. Co. Ltd. NO has received research support or speakers’ honoraria from, or has served as a consultant to, Sumitomo Dainippon, Eisai, Otsuka, KAITEKI, Mitsubishi Tanabe, Shionogi, Eli Lilly, Mochida, DAIICHI SANKYO, Nihon Medi-Physics, Takeda, Meiji Seika Pharma, EA Pharma, Pfizer, MSD, Lundbeck Japan, Taisho Pharma, Janssen, UCB, Shionogi, Nihon Medi-Physics, Tsumura, Novartis, and Astellas. MI has received speakers’ honoraria from Sumitomo Pharma, Eisai, Otsuka, Tanabe Mitsubishi, Mochida, Takeda, Meiji Seika Pharma, EA Pharma, Viatris, MSD, Janssen, Lundbeck, and Yoshitomi.